The Dry Age-Related Macular Degeneration Market Size was valued at USD 11.12 billion in 2022 and is expected to reach USD 20.92 billion by 2030 and grow at a CAGR of 8.22% over the forecast period 2023-2030.
Several key factors are propelling this upward trajectory:
- Rising aging population: As life expectancy increases, the prevalence of dry AMD naturally rises, necessitating more diagnostic tools and treatment options.
- Increased awareness and early diagnosis: Growing campaigns and improved screening technologies are leading to earlier diagnoses, enabling intervention before significant vision loss occurs.
- Advancements in treatment options: While a cure remains elusive, new therapies, including gene therapy and anti-angiogenic drugs, are offering promising results and hope for future breakthroughs.
- Focus on personalized medicine: Researchers are exploring genetic and biomarker-based approaches to tailor treatment strategies for individual patients, improving efficacy and minimizing side effects.
- Emphasis on patient-centric care: Telemedicine and remote monitoring tools are facilitating convenient access to specialists and ongoing care, enhancing patient quality of life.
Navigating the Landscape: Segmentation of the Dry AMD Market:
- By Stages:
- Early AMD: The majority of patients fall into this stage, often presenting with drusen deposits but minimal vision loss.
- Intermediate AMD: Characterized by vision disturbances and pigmentary changes, this stage necessitates close monitoring and potential initiation of treatment.
- Late AMD: The most advanced stage, it can lead to significant vision loss and requires specialized care and management.
- By End User:
- Hospitals & Clinics: The primary providers of diagnostic services and treatment options, equipped with specialized equipment and trained personnel.
- Diagnostic Centers: Play a crucial role in early detection and initial evaluation using advanced imaging technologies.
- Academic Research Institutes: Drive discovery and research into new diagnostic methods and treatment avenues.
- Others: Home healthcare services and specialized AMD clinics are emerging to offer dedicated care.
- By Age Group:
- Above 40 Years: Individuals in this age range can develop early AMD, highlighting the importance of regular eye examinations.
- Above 60 Years: This group represents the highest prevalence of intermediate AMD, demanding targeted screening and intervention strategies.
- Above 75 Years: Late AMD cases are more common in this age group, requiring specialized care and support services.
- By Diagnosis & Treatment:
- Treatment: The market currently focuses on managing symptoms and slowing disease progression through vitamins, nutritional supplements, and potential future gene therapy and anti-angiogenic drugs.
- Diagnosis: Advanced imaging techniques like optical coherence tomography play a vital role in early detection and monitoring disease progression.
- By Route Of Administration:
- Oral: Vitamins and nutritional supplements are typically taken orally for their long-term impact on retinal health.
- Injectables: Anti-angiogenic drugs may be administered through intravitreal injections for targeted therapy.
- By Region:
- North America: Leads the market due to higher awareness, advanced healthcare infrastructure, and rapid adoption of new technologies.
- Europe: A mature market with established healthcare systems, facing potential economic challenges impacting growth.
- Asia Pacific: Projected to witness the fastest growth driven by a large aging population, rising healthcare spending, and increasing awareness.
- Latin America and Africa: Emerging markets with significant future potential as healthcare infrastructure and access to technology improve.
Shaping the Future: Key Players and Emerging Trends:
Key players like Santen Pharmaceuticals Inc., Ocumension Therapeutics Co. Ltd, Iveric Bio, Eyestem Research Pvt Ltd, Allergan plc, Bausch Health, Belite Bio Inc., Kubota Vision Inc., Alimera Science Inc., Phio Pharmaceuticals Corp,Yuyang DNU Co., Ltd, Stealth Biotherapeutics Inc. and other players..
Some of the key trends shaping the future of the dry AMD market include:
- Development of novel gene therapies: Targeted gene editing holds immense potential for treating the root cause of the disease.
- Combination therapies: Combining different treatment modalities may offer enhanced efficacy and broader patient accessibility.
- Artificial intelligence and machine learning: AI-powered tools are aiding in early diagnosis, treatment personalization, and drug discovery.
- Focus on prevention and lifestyle modification: Promoting healthy dietary choices, smoking cessation, and managing other risk factors may slow disease progression.
- Global collaborative efforts: Increased collaboration between researchers, pharmaceutical companies, and healthcare providers
Other Reports You May Like:
Nano Biotechnology Market Growth
Growth Hormone Deficiency Market Growth
Medical Device Cleaning Market Growth
Artificial Cervical Disc Market Growth
About US:
SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.
We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.
Contact Us:
Akash Anand – Head of Business Development & Strategy,
info@snsinsider.com,
Phone: +1-415-230-0044 (US) | +91-7798602273 (IND),
Website: https://www.snsinsider.com